Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fostamatinib - Rigel Pharmaceuticals

Next Previous
Drug Profile

Fostamatinib - Rigel Pharmaceuticals

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib disodium hexahydrate; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; TAVALISSE; Tavalisse; TAVLESSE

Latest Information Update: 18 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Grifols; JW Pharmaceutical; Kissei Pharmaceutical; Knight Therapeutics; National Heart, Lung and Blood Institute; Rigel Pharmaceuticals; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt University Medical Center
  • Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura
  • Preregistration COVID 2019 infections
  • Phase III Autoimmune haemolytic anaemia
  • Phase II/III COVID-19 pneumonia
  • No development reported Graft-versus-host disease; Ovarian cancer; Waldenstrom's macroglobulinaemia
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; IgA nephropathy; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T-cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 30 Sep 2025 Knight receives a rejection from ANVISA regarding its marketing authorization application for Tavalisse® in Brazil, before September 2025
  • 28 Jul 2025 Ikena Oncology has merged with Inmagene to form ImageneBio
  • 01 Jul 2025 Launched for Idiopathic thrombocytopenic purpura (Treatment-experienced, In adults) in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top